Dieses Bild ist zur Zeit nicht verfügbar.

Recent Advances in Prostate Cancer and BPH

F.H. Schroeder(Herausgeber*in)
Taylor & Francis Ltd (Verlag)
1. Auflage
Erschienen am 15. November 1996
Buch
Hardcover
302 Seiten
978-1-85070-784-4 (ISBN)
127,17 €inkl. 7% MwSt.
Artikel ist vergriffen; keine Neuauflage
This is the most complete, authoritative reference work available on the newest developments in treating prostate cancer and benign hypertrophic hyperplasia. It contains more than 30 state-of-the-art contributions by world-class specialists covering every major topic in prostate cancer and BPH today. Several chapters deal with PSA for screening and prognosis and many present original new data from European studies not usually included in American texts.
 
This is the most complete, authoritative reference work available on the newest developments in treating prostate cancer and benign hypertrophic hyperplasia. It contains more than 30 state-of-the-art contributions by world-class specialists covering every major topic in prostate cancer and BPH today. Several chapters deal with PSA for screening and prognosis and many present original new data from European studies not usually included in American texts.
Sprache
Englisch
Verlagsort
London
Großbritannien
Zielgruppe
Für höhere Schule und Studium
Für Beruf und Forschung
Gewicht
998 gr
ISBN-13
978-1-85070-784-4 (9781850707844)
Schlagworte
Schweitzer Klassifikation
Thema Klassifikation
Newbooks Subjects & Qualifier
DNB DDC Sachgruppen
Dewey Decimal Classfication (DDC)
BIC 2 Klassifikation
BISAC Klassifikation
Rationale for trials of screening for prostate cancer. Utility of total serum PSA, free total ratio, age specific reference ranges, and PSAD. BPH: characteristics of the disease observed in the general population. Trends in post-radical prostatectomy incontinence. The ratio of free to total prostate specific antigen level. Chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial. PSA and the natural course of prostate cancer. Can progression of prostate cancer be predicted by pretreatment parameters? Watchful waiting as a treatment option in the management of clinical localized prostate cancer. Sexual function before and after radical prostatectomy. Intermittent androgen suppression. 5alpha-Reductase inhibition of the treatment of prostate cancer. European randomized study of screening for prostate cancer. Endocrine therapy. PSA and other serum markers as prognostic factors of response duration and patient survival in metastatic prostate carcinoma. Early vs. d elayed endocrine treatment. Combination therapy. Free and total PSA. Can we safely exclude patients with confined prostate cancer from treatment. Western diet and prostate cancer. Incontinence after radical prostatectomy. Preservation of continence after radical prostatectomy. Radical prostatectomy in the treatment of locally confined prostate cancer. Finasteride in BPH. Characteristics of prostate cancer. Molecular alterations associated with prostate cancer development. Post-radical prostatectomy incontinence. Antiandrogens as monotherapy. The European randomized study of screening for prostate cancer. New and old interventions in BPH. intermittent endocrine treatment. Rising prostate-specific antigen. Hot flushes under endocrine treatment. PSA response following radical radiation therapy. Index.